Dear Friends,

In 2021, we have continued our growth and expanding outreach and access to mast cell disease education, resources and support to over 15,000 patients and caregivers. TMS is committed to being the messengers of inspirational patient experience and effect measurable changes in recognition, diagnosis, testing, and treatment of all forms of mast cell disease, with transformative improvements in quality of life for our patients and families.

The Board adopted a three-year strategic plan to boldly grow our organization and impact through six core pillars: Patient Programs, Physician Education, Research Grant Making, Patient Centered Research, Advocacy & Collaborations, and Governance & Financial Sustainability. Our strategic pillars are grounded by our mission and developed based on a series of interviews from patients, caregivers, volunteers, stakeholders and our recent needs assessment involving approximately 9,000 members to address increased patient impact and commitment to growth objectives. This strategic plan embodies our continuing commitment to listen to the diverse voices of our community, strengthen our partnerships with other organizations, and share findings and benefits from our work.

TMS & The American Academy of Allergy, Asthma & Immunology (AAAAI) granted $60,000 to Dr. Daniel Dwyer with Brigham and Women’s Hospital, Boston, MA to advance “single-cell characterization of cutaneous mast cells in mastocytosis and hereditary alpha-tryptasemia. As research grantmaking is one of our core pillars, we plan to allocate up to 25% of unrestricted net revenue to support the funding of research grants on an annual basis.

2022 brings expansion of our organization and programs aiming to educate both patients and physicians on mast cell diseases. Through continued collaboration, we have the potential and will create lasting change to serve the community and advance research of mast cell disease.

Lauren Denton, MA  Valerie M. Slee, RN, BSN
Executive Director  Chair, Board of Directors

Reflecting on the past twenty years, today and as we look forward, we remain deeply committed to Patients First, and both the education of patients, families and physicians and research to improve access to care, more effective treatments, improved quality of life and curative therapies.

~ Valerie Slee, RN, BSN, Board Chair
# Our IMPACT

## 2021 Financial Summary

**Assets**
- Cash and cash equivalents $758,959
- Investments $250,787
- Other Current Assets $18,960
- **Total Assets** $1,028,705

**Liabilities & Net Assets**
- Accounts Payable $7,165
- Unrestricted Assets $838,868
- Restricted Assets $182,672
- **Total Net Assets** $1,021,540
- **Total Liabilities & Net Assets** $1,028,705

**Revenue**
- Unrestricted $361,456
- Temporarily Restricted $165,745
- Interest and Other Income $14,987
- Unrealized Gain on Investment $150,447
- **Total Revenue** $560,928

**Expenses**
- Admin & General $191,467
- Program Services $89,177
- Fundraising $6,770
- **Total Expenses** $287,413
- **Change in Net Assets** $256,346

## 2021 Board of Directors

Chair Valerie Sle, Vice Chair of Education and Patient Support Jan Hempstead, Vice Chair of Community Engagement Courtney Rabb, Vice Chair Research Celeste Finnerty, Interim Treasurer Rose Schultz, Secretary Judith Emmel.

## 2021–2023 Medical Advisory Board


## 2021-2023 Medical Advisory Board


## 2021 ANNUAL REPORT

**Network of over 15,000**
- 32 Virtual Support Groups
- 1,000+ attendees at 24th National Conference (US & 15 Countries)
- 1,000 Nurse Line Email Support
- FDA Patient Listening Session on Mastocytosis
- 12 Patient Voice Forums
- Patient Perspective Publication on mast cell activation symptoms
- COVID-19 Impact/Needs Assessment Surveys
- Granted $40,000 towards research and education